<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102157">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01774591</url>
  </required_header>
  <id_info>
    <org_study_id>12-1179</org_study_id>
    <nct_id>NCT01774591</nct_id>
  </id_info>
  <brief_title>Effect of Azilsartan on Aldosterone in Postmenopausal Females</brief_title>
  <official_title>Effect of Azilsartan on Aldosterone in Postmenopausal Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the research is to evaluate the effect of azilsartan medoximil on blood
      pressure and urinary aldosterone levels in postmenopausal females.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized, placebo-controlled trial of post-menopausal females with stage 1
      hypertension. The goal is to randomize 40 post-menopausal females with stage 1 hypertension
      and assess whether azilsartan reduces urinary aldosterone levels. Additionally, a small
      sub-study comparing pre-menopausal and post-menopausal female aldosterone levels was
      performed as well as the presence of aldosterone production in fat cell cultures of a subset
      of 3 patients in the randomized trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effect of an angiotensin receptor blocker (azilsartan medoximil) on blood pressure in postmenopausal females.</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of an angiotensin receptor blocker (azilsartan medoximil) on urinary aldosterone levels in postmenopausal females.</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>azilsartan medoximil.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to azilsartan medoximil arm will take 80 mg of azilsartan medoximil tablets by mouth each day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects randomized to the placebo arm will take 80 mg of placebo tablets by mouth each day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan medoximil</intervention_name>
    <description>All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.</description>
    <arm_group_label>azilsartan medoximil.</arm_group_label>
    <other_name>Edarbi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Ages 45-70

          -  Post-menopause: have not had a menstrual period for one year or more

          -  Diagnosed with Stage 1 hypertension

          -  Body Mass Index (BMI) greater than or equal to 28

        Exclusion Criteria:

          -  Male

          -  Diagnosed with Stage 2 hypertension

          -  Stage 1 hypertension requiring more than one agent

          -  Pregnancy or attempting pregnancy

          -  Use of oral contraceptive pills

          -  Use of hormone replacement therapy

          -  Use of steroids

          -  Stage 3 or greater kidney disease

          -  Diabetes mellitus

          -  untreated hypothyroidism or hyperthyroidism

          -  primary hyperaldosteronism

          -  Cushing's disease

          -  obstructive sleep apnea

          -  chronic illness, e.g. chronic liver disease

          -  NYHA class III or greater heart failure

          -  moderate to severe lung disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Bakris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 8, 2016</lastchanged_date>
  <firstreceived_date>January 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post Menopause</keyword>
  <keyword>Female</keyword>
  <keyword>Obese</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
